ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Curia Completes Acquisition of LakePharma

Adds biologics development capabilities, expertise and scale from discovery through GMP manufacturing

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has completed the transaction to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts and Texas. With the addition of LakePharma, Curia offers deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production.

“The completion of LakePharma transforms our biologics offering, enabling us to provide end-to-end capabilities to customers, based on deep scientific expertise and an integrated technology platform,” said Curia Chairman and CEO John Ratliff. “Together with Integrity Bio, now part of Curia, this transaction represents a major milestone in our growth journey and means we can deliver seamless solutions and expanded capacity for biologics customers. I’m delighted to welcome our new colleagues from LakePharma to the global Curia community and to work with them to advance our customers from curiosity to cure.”

LakePharma will operate as part of Curia’s Research and Development division, led by Christopher Conway, president, R&D. Hua Tu, Ph.D., LakePharma’s founder and CEO, also will serve on Curia’s executive team as chief technology officer. LakePharma and its “The Biologics Company” brand will migrate to the Curia brand in the future. It will continue to use its name for an interim period, adding “Now part of Curia” to its logo.

About Curia

Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s more than 3,700 employees at 29 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

@CuriaCDMO completes acquisition of @LakePharma, transforming its biologics offering

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.16
+0.00 (0.00%)
AAPL  277.55
+0.00 (0.00%)
AMD  214.10
+0.00 (0.00%)
BAC  52.99
+0.00 (0.00%)
GOOG  320.28
+0.00 (0.00%)
META  633.61
+0.00 (0.00%)
MSFT  485.50
+0.00 (0.00%)
NVDA  180.26
+0.00 (0.00%)
ORCL  204.96
+0.00 (0.00%)
TSLA  426.58
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.